Inventor

PASTAN IRA H

US71 patents

⚠️ This page may combine multiple inventors who share the name “PASTAN IRA H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

PASTAN IRA H

US HEALTH

Recombinant disulfide-stabilized polypeptide fragments having binding specificity

Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects

Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use

Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use

Mutated anti-cd22 antibodies and immunoconjugates

Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point

Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity

Recombinant disulfide-stabilized polypeptide fragments having binding specificity

Constructs encoding recombinant antibody-toxin fusion proteins

Recombinant antibody-toxin fusion protein

Recombinant antibody-toxin fusion protein

Fusion proteins comprising circularly permuted ligands

Selectively cytotoxic IL-4-PE40 fusion protein

Anti-CD22 chimeric antigen receptors

Anti-mesothelin chimeric antigen receptors

Mesothelin antibodies and methods for eliciting potent antitumor activity

Human anti-mesothelin monoclonal antibodies

Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use

Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins

M971 chimeric antigen receptors

Human monoclonal antibodies specific for CD22

Immunogenic peptides and methods of use

Modified Pseudomonas exotoxin A

Mesothelin domain-specific monoclonal antibodies and use thereof

Mesothelin domain-specific monoclonal antibodies and use thereof

M971 chimeric antigen receptors

Anti-BCMA polypeptides and proteins

M971 chimeric antigen receptors

PASTAN IRA H

Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes

Pseudomonas exotoxin A with less immunogenic B cell epitopes

Pseudomonas exotoxin a with reduced immunogenicity

Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes

Mutated Pseudomonas exotoxins with reduced antigenicity

Recombinant immunotoxin targeting mesothelin

US ARMY

Recombinant pseudomonas exotoxin with increased activity

Recombinant pseudomonas exotoxin with increased activity

Monoclonal antibodies to prostate cells

UNIV DUKE

Antibodies and immunotoxins that target human glycoprotein NMB

Dual specific immunotoxin for brain tumor therapy

Human bispecific EGFRvIII and CD3 antibody engaging molecules

NAT INST HEALTH

Recombinant pseudomonas exotoxin with increased activity

SCHLOM JEFFREY

Immunogenic peptides and methods of use

DIMITROV DIMITER S

Human monoclonal antibodies specific for CD22

US AS REPRESENTED BY THE DEPAR

Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells

UNIV ILLINOIS

Compositions for clones containing DNA sequences associated with multidrug resistance in human cells

CETUS CORP

Anti-human ovarian cancer immunotoxins and methods of use thereof

THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES

Human monoclonal antibodies specific for CD22

BIGNER DARELL D

Bispecific EGFRvIII x CD3 antibody engaging molecules

THE GOVERNMENT OF THE U S A AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES

Human monoclonal antibodies specific for CD22